chr1-156137233-G-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The ENST00000368300.9(LMNA):c.1608+1G>A variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Consequence
LMNA
ENST00000368300.9 splice_donor, intron
ENST00000368300.9 splice_donor, intron
Scores
5
1
1
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 10.0
Genes affected
LMNA (HGNC:6636): (lamin A/C) The protein encoded by this gene is part of the nuclear lamina, a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Alternative splicing results in multiple transcript variants. Mutations in this gene lead to several diseases: Emery-Dreifuss muscular dystrophy, familial partial lipodystrophy, limb girdle muscular dystrophy, dilated cardiomyopathy, Charcot-Marie-Tooth disease, and Hutchinson-Gilford progeria syndrome. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.05964912 fraction of the gene. No cryptic splice site detected. Exon removal is inframe change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 1-156137233-G-A is Pathogenic according to our data. Variant chr1-156137233-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 66853.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LMNA | NM_170707.4 | c.1608+1G>A | splice_donor_variant, intron_variant | ENST00000368300.9 | NP_733821.1 | |||
LMNA | NM_005572.4 | c.1608+1G>A | splice_donor_variant, intron_variant | ENST00000677389.1 | NP_005563.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LMNA | ENST00000368300.9 | c.1608+1G>A | splice_donor_variant, intron_variant | 1 | NM_170707.4 | ENSP00000357283.4 | ||||
LMNA | ENST00000677389.1 | c.1608+1G>A | splice_donor_variant, intron_variant | NM_005572.4 | ENSP00000503633.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 32
GnomAD4 exome
Cov.:
32
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Dilated cardiomyopathy 1A Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Mar 01, 2019 | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2,PP5. - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Feb 02, 2022 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0103 - Dominant negative, loss of function and gain of function are known mechanisms of disease in this gene. Some missense variants have been reported to result in a toxic gain of function or dominant negative effect and are associated with childhood-onset disease or skeletal muscle involvement, while other variants have been reported to result in a loss of function and haploinsufficiency, and are associated with adult-onset cardiac and myopathy disorders (PMID: 17377071). (I) 0108 - This gene is associated with both recessive and dominant disease. There are multiple phenotypes associated with this gene, however dilated cardiomyopathy type 1A (CMD1A) (MIM#115200) and Emery-Dreifuss muscular dystrophy 2 (MIM#181350; formerly limb-girdle muscular dystrophy type 1B (LGMD1B)) are inherited in a dominant manner (OMIM). (I) 0115 - Variants in this gene are known to have variable expressivity. The majority of individuals published with this variant were diagnosed with LGMD1B, however a small number of cases were not reported with skeletal muscle involvement and considered to have CMD1A only. It has been suggested that individuals initially referred for DCM also be assessed for a history of mild muscle weakness (PMID: 19446900). (I) 0211 - Canonical splice site variant without proven consequence on splicing (no functional evidence available). (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0505 - Abnormal splicing is predicted by in silico tools and affected nucleotide is highly conserved. (SP) 0701 - Other splice variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. At least four alternative variants, at the same nucleotide and in the surrounding splice region, have previously been reported in more than ten unrelated individuals with either LGMD1B or CMD1A (ClinVar, PMIDs: 24459210, 24915601, 29693488, 31744510, 33304817). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. The variant has previously been reported in at least eight probands, predominantly in association LGMD1B, however it has also been reported for CMD1A only (ClinVar, VCGS, PMIDs: 13129702, 15678000, 19446900, 31931689). (SP) 0901 - This variant has strong evidence for segregation with disease. The variant has previously been shown to segregation with disease in two LGMD1B families and one CMD1A family, in a total of seven affected genotyped individuals and two obligate carriers (VCGS, PMIDs: 15678000, 19446900, 31931689). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Experiments using transplanted heart tissue from an LGMD1B individual showed increased levels of phosphorylated ERK1/2 compared to controls, similar to the increased activity observed in in vitro and in vivo models of other pathogenic LMNA variants (PMID: 22068161). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Neuromuscular disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 10, 2014 | The 1608+1G>A variant in LMNA gene was absent from large population studies but has been reported in one individual with limb-girdle muscular dystrophy type 1B (LGMD1B) with DCM and segregated with disease in 4 affected family members inclu ding 2 obligate carriers (Ambrosi 2009). It was also detected in 2 additional in dividuals with LGMD1B and conduction system disease as well as one affected fami ly member (Ben Yaou 2005). This variant occurs in the invariant region (+/- 1,2) of the splice consensus sequence and is predicted to cause altered splicing lea ding to an abnormal or absent protein. In summary, this variant meets our criter ia to be classified as pathogenic for LGMD1B in an autosomal dominant manner (ht tp://www.partners.org/personalizedmedicine/LMM) based upon segregation studies, absence from controls, predicted impact to the protein. - |
Charcot-Marie-Tooth disease type 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 24, 2023 | ClinVar contains an entry for this variant (Variation ID: 66853). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant is also known as IVS9+1G>A. Disruption of this splice site has been observed in individual(s) with autosomal dominant limb-girdle muscular dystrophy (PMID: 15678000, 19446900). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 9 of the LMNA gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in LMNA are known to be pathogenic (PMID: 18585512, 18926329). - |
Hutchinson-Gilford syndrome;C0410190:Emery-Dreifuss muscular dystrophy 2, autosomal dominant;C0796031:Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome;C1449563:Dilated cardiomyopathy 1A;C1720860:Familial partial lipodystrophy, Dunnigan type;C1854154:Charcot-Marie-Tooth disease type 2B1;C1857829:Heart-hand syndrome, Slovenian type;C2750035:Emery-Dreifuss muscular dystrophy 3, autosomal recessive;C2750785:Congenital muscular dystrophy due to LMNA mutation;C5399785:Mandibuloacral dysplasia with type A lipodystrophy;C5676942:Restrictive dermopathy 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 18, 2022 | - - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 04, 2024 | The c.1608+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 9 of the LMNA gene. Alterations that disrupt the canonical splice site are expected to result in aberrant splicing. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and will result in the creation or strengthening of a novel splice donor site. The resulting transcript is predicted to be in-frame and is not expected to trigger nonsense-mediated mRNAdecay; however, direct evidence is unavailable. The exact functional effect of the altered amino acid sequence is unknown; however, a significant portion of the protein is affected and the impacted region is critical for protein function (Ambry internal data). This variant (also referred to as IVS9+1G>A) has been detected in individuals with features consistent with laminopathies, including dilated cardiomyopathy, cardiac conduction disease, and limb-girdle muscular dystrophy, and has shown segregation with disease features in families (Ambrosi P et al. Int J Cardiol, 2009 Nov;137:e75-6; Ben Yaou R et al. Rev Neurol (Paris), 2005 Jan;161:42-54; Ramchand J et al. J Am Heart Assoc, 2020 Jan;9:e013346). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. - |
not provided Other:1
not provided, no classification provided | literature only | Epithelial Biology; Institute of Medical Biology, Singapore | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
D;D;D;D;D;D;D;D;D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DG_spliceai
Position offset: -30
DS_DL_spliceai
Position offset: -1
Find out detailed SpliceAI scores and Pangolin per-transcript scores at